

JUL 13 2001

Sheet 1 of 1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
25020-601BSERIAL NO.
09/360,242LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENTAPPLICANT
McDonald *et al.*FILING DATE
July 22, 1999GROUP
1647

RECEIVED

JUL 17 2001

U.S. PATENT DOCUMENTS

TEC-CENTER 1600/2900

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>AK</i>	A	5	6	1	4	1	9	1	03/25/97	Puri <i>et al.</i>	424	178.1	03/15/95
<i>AK</i>	B	5	7	5	0	5	6	5	05/12/98	Cai <i>et al.</i>	514	473	05/31/95

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
--	--	-----------------	--	--	--	--	--	--	------	---------	-------	--------------	-----------------------

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>AK</i>	C	Callard, R. and A. Gearing. <i>THE CYTOKINE FACTS BOOK</i> San Diego: Academic Press, 1994. pg.3.
	D	Coles <i>et al.</i> "Monoclonal Antibody Treatments Exposes Three Mechanisms Underlying the Clinical Course of Multiple Sclerosis," <i>Ann. Neurol.</i> 46:296-304 (1999).
	E	Gong <i>et al.</i> "RANTES and MCP-3 Antagonists Bind Multiple Chemokine," <i>The Journal to Biological Chemistry</i> 271: 10521-10527 (1996).
	F	Huitinga <i>et al.</i> "Suppression of Experimental Allergic Encephalomyelitis in Lewis Rats After Elimination of Macrophages," <i>J. Exp. Med.</i> 172: 1025-1033 (1990).
	G	McDonald <i>et al.</i> "The therapeutic potential of chemokine-toxin fusion proteins," <i>IDrugs</i> 4(4): 427-442 (2001).
	H	Ofulue, A.F. and M. Ko. "Effects of depletion of neuriphils or macrophages on development of cigarette smoked-induced emphysema," <i>Am. J. Physiol.</i> 277(Lung Cell. Mol. Physiol. 21):L97-L105 (1999).
	I	Paolillo <i>et al.</i> "Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H," <i>Neurology</i> 53: 751-757 (1999).
	J	Popovich <i>et al.</i> "Depletion of Hematogenous Macrophages Promotes Partial Hindlimb Recovery and Neuroanatomical Repair after Experimental Spinal Cord Injury," <i>Experimental Neurology</i> 158: 351-365 (1999).
<i>C</i>	K	Pouvreau <i>et al.</i> "Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis," <i>J. Neuroimmunol.</i> 86(2): 171-181 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET
25020-601BSERIAL NO.
09/360,242LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
McDonald et al.FILING DATE
July 22, 1999

GROUP

RECEIVED

JUL 17 2001

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

TECH CENTER 1600-2900

<i>MC</i>		Sandhu, Protein engineering of antibodies, <i>Crit. Rev. Biotech.</i> <u>12</u> :437-62, 1992
<i>NR</i>	NR	Sandvig and Van Deurs, Endocytosis, intracellular transport, and cytotoxic action of shiga toxin and ricin, <i>Physiol. Rev.</i> <u>76</u> :949-66, 1996
<i>NS</i>	NS	Santerre <i>et al.</i> , Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells, <i>Gene</i> , <u>30</u> : 147-56, 1984
<i>NT</i>	NT	Sarver, <i>et al.</i> , Bovine papilloma virus deoxyribonucleic acid: a novel eucaryotic cloning vector, <i>Mol. Cell. Biol.</i> <u>1</u> : 486-96, 1981
<i>NU</i>	NU	Schall <i>et al.</i> , Chemokines, leukocyte trafficking, and inflammation, <i>Current Biol.</i> , <u>6</u> : 865-73, 1994
<i>NV</i>	NV	Schaniel <i>et al.</i> , Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells, <i>J. Exp. Med.</i> <u>188</u> (3):451-463 (1998)
<i>NW</i>	NW	Schrier <i>et al.</i> , Role of chemokines and cytokines in a reactivation model of arthritis in rats induced by injection with streptococcal cell walls, <i>J. of Leukocyte Biology</i> <u>63</u> :359-363 (1998)
<i>NX</i>	NX	Schrier <i>et al.</i> , the effects of the nude (<i>nu/nu</i>) mutation on bleomycin-induced pulmonary fibrosis, <i>Am Rev Respir Dis</i> <u>12</u> :614-617 (1983)
<i>NY</i>	NY	Seetharam <i>et al.</i> , Increased cytotoxic activity of <i>Pseudomonas</i> exotoxin and two chimeric toxins ending in KDEL*, <i>J. Biol. Chem.</i> <u>266</u> :17376-17381 (1991)
<i>NZ</i>	NZ	Selmaj <i>et al.</i> , Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I, <i>J. Neuroimmunol.</i> , <u>56</u> : 135-41, 1995
<i>OA</i>	OA	Senter <i>et al.</i> , Novel photocleavable protein crosslinking reagents and their use in the preparation of antibody-toxin conjugates, <i>Photochem. Photobiol.</i> <u>42</u> :231-237 (1985)
<i>OB</i>	OB	Shirozu <i>et al.</i> , Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene, <i>Genomics</i> , <u>28</u> : 495-500, 1995
<i>OC</i>	OC	Shirozu <i>et al.</i> , Characterization of novel secreted and membrane proteins isolated by the signal sequence trap method, <i>Genomics</i> , <u>37</u> : 273-80, 1996
<i>OD</i>	OD	Singer <i>et al.</i> , Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences, <i>J. Immunol.</i> <u>150</u> :2844-67, 1993
<i>OE</i>	OE	Sippy <i>et al.</i> , Increased expression of tumor necrosis factor- α receptors in the brains of patients with AIDS, <i>J. Acquir. Defic. Syndr. Hum. Retrovirol.</i> , <u>10</u> : 511-21, 1995

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
25020-601BSERIAL NO.
09/360,242LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
McDonald et al.FILING DATE
July 22, 1999GROUP
1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
pk	A 6 1 0 0 3 8 7	08/08/00	Hermann et al.	536	23.4	02/28/97

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

RECEIVED

MAR 13 2001

TECH CENTER 1600,2900

EXAMINER


DATE CONSIDERED

8/17/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

September 13, 2000

EORM PTO-1449 (Modified)

ATTY. DOCKET NO.
25020-601BSERIAL NO.
09/360,242LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
McDonald et al.FILING DATE
July 22, 1999GROUP
1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
	A	9 7 0 0 9 4 6	01/09/97	PCT			
	B	9 8 4 6 6 4 5	10/22/98	PCT			
	C	9 8 4 6 7 8 8	10/22/98	PCT			
	D	9 9 5 4 4 4 0	10/28/99	PCT			
	E	9 9 5 8 6 7 8	11/18/99	PCT			
	E	0 0 0 6 6 0 5	02/10/00	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

5/17/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

September 13, 2000